Arkolith/Insider Trading/AKTS/Form 4

Kim Helen Susan

Director, 10% OwnerAktis Oncology, Inc. (AKTS) · full profile →Form 4 · filed Jan 12, 2026
Net Buying
Open-Market Buys
$15.0M
Open-Market Sells
$0
Net Open-Market Flow
$15.0M
Transactions
8
4 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)4.9M——4.9M
Jan 12, 2026Buy(P)23K$18.00$406K157K
Jan 12, 2026Conversion(C)135K——135K
Jan 12, 2026Buy(P)812K$18.00$14.6M5.7M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)14.8M—$00
Jan 12, 2026Conversion(C)101K—$00
Jan 12, 2026Conversion(C)3.6M—$00
Jan 12, 2026Conversion(C)412K—$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-010566) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Aktis Oncology, Inc.

Build

Ask your agent about AKTS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001193125-26-010566"
Ask your agent
Use Arkolith to summarize insider buying and selling at Aktis Oncology, Inc.
over the last 90 days and cite the filings.